As part of the medtech giant’s Spyral HTN global clinical program, three-year data from the Spyral HTN-ON MED and GSR-Define trials were presented at EuroPCR 2022 as late-breaking clinical trials demonstrating the benefit of the Symplicity blood pressure procedure with Simplicity Spyral.
The Medtronic RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the kidneys that can become overactive and cause high blood pressure. It is currently limited to investigational use in the United States, Japan and Canada.
Results from the first 80 patients in the Spyral HTN-ON MED trial show improved blood pressure control with significantly high…